Arthritis und Rheuma 2011; 31(04): 257-264
DOI: 10.1055/s-0037-1618076
Systemischer Lupus erythematodes
Schattauer GmbH

Schwangerschaft bei systemischem Lupus erythematodes

Wie hoch ist das Risiko im 21. Jahrhundert?Pregnancy in systemic lupus erythematosushow high is the risk in the 21st century?
R. Fischer-Betz
1   Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
26 December 2017 (online)

Zusammenfassung

Der systemische Lupus erythematodes (SLE) ist eine komplexe Autoimmunerkrankung und betrifft vor allem Frauen im reproduktiven Alter. Eine Konsequenz daraus ist die häufige Interaktion mit Kinderwunsch und Schwangerschaft. Der Ausgang von Schwangerschaften bei SLE hat sich in den vergangenen Jahrzehnten unzweifelhaft verbessert, mit einem deutlichen Anstieg der Anzahl an Lebendgeburten. Dennoch kann eine Schwangerschaft für Lupus-Patientinnen mit erheblichen mütterlichen und kindlichen Risiken verbunden sein. Eine adäquate Betreuung in der Schwangerschaft umfasst eine gynäkologisch-rheumatologische Zusammenarbeit, ein abgesprochenes und definiertes Management sowie eine erfahrene Neonatologie. Jede SLE-Schwangerschaft sollte im Rahmen eines präkonzeptionellen Gesprächs geplant werden, um das individuelle Risiko einzuschätzen.

Summary

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a strong feminine predilection. A normal consequence of the epidemiology of lupus is therefore the frequent interaction with pregnancy. The outcome of pregnancy for women with SLE has undoubtedly improved with a significant increase in live birth rate over the last decades. However, pregnancy in women with lupus can still be associated with significant maternal and fetal complications. Adequate pregnancy care of women with SLE comprises a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit. Pregnancy should be planned following a preconceptional visit for assessing the individual risk.

 
  • Literatur

  • 1 Fischer-Betz R, Wessel E, Richter J. et al. Lupus in Germany: analysis within the German lupus selfhelp organization (LULA). Z Rheumatol 2005; 64 (02) 111-122.
  • 2 McElhone K, Abbott J, Gray J. et al. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus 2010; 19 (14) 1640-1647.
  • 3 Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol 2005; 32 (09) 1709-1712.
  • 4 Yan Yuen S, Krizova A, Ouimet JM. et al. Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) is Improving: Results from a Case Control Study and Literature Review. Open Rheumatol J 2008; 2: 89-98.
  • 5 Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007; 33 (02) 237-252.
  • 6 Clark CA, Spitzer KA, Nadler JN. et al. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003; 30 (10) 2127-2132.
  • 7 Andrade R, Sanchez ML, Alarcón GS. et al. Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected]. Clin Exp Rheumatol 2008; 26 (02) 268-274.
  • 8 Clowse ME, Jamison M, Myers E. et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199 (02) 127.e1-127.e6.
  • 9 Ruiz-Irastorza G, Khamashta MA. Evaluation of systemic lupus erythematosus activity during pregnancy. Lupus 2004; 13: 679-682.
  • 10 Urowitz MB, Gladman DD, Farewell VT. et al. Lupus and pregnancy studies. Arthritis Rheum 1993; 36 (10) 1392-1397.
  • 11 Petri M. The Hopkins Lupus Pregnancy Center: ten key issues in management. Rheum Dis Clin North Am 2007; 33 (02) 227-235.
  • 12 Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34 (12) 1538-1545.
  • 13 Clowse ME, Magder LS, Witter F. et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52 (02) 514-521.
  • 14 Lê Huong D, Wechsler B, Vauthier-Brouzes D. et al. Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies. Br J Rheumatol 1997; 36 (07) 772-777.
  • 15 Clowse ME, Magder L, Witter F. et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640-3647.
  • 16 Levy RA, Vilela VS, Cataldo MJ. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: doubleblind and placebo-controlled study. Lupus 2001; 10 (06) 401-404.
  • 17 Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 2006; 15 (03) 148-155.
  • 18 Smyth A, Oliveira GH, Lahr BD. et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5 (11) 2060-2068.
  • 19 Day CJ, Lipkin GW, Savage CO. Lupus nephritis and pregnancy in the 21st century. Nephrol Dial Transplant 2009; 24 (02) 344-347.
  • 20 Imbasciati E, Tincani A, Gregorini G. et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 2009; 24 (02) 519-525.
  • 21 Milne F, Redman C, Walker J. et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. Br Med J 2005; 330: 576-580.
  • 22 Chakravarty EF, Colón I, Langen ES. et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005; 192 (06) 1897-1904.
  • 23 Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54 (03) 899-907.
  • 24 Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. Br Med J 2005; 330: 565.
  • 25 Askie LM, Duley L, Henderson-Smart DJ. et al. PARIS Collaborative Group.Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 26 369 (9575) 1791-1798.
  • 26 Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376 (9751) 1498-1509.
  • 27 Nodler J, Moolamalla SR, Ledger EM. et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 2009; 9: 11.
  • 28 Yamada H, Atsumi T, Kobashi G. et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009; 79 (02) 188-195.
  • 29 Ruffatti A, Calligaro A, Hoxha A. et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010; 62 (03) 302-307.
  • 30 Bramham K, Hunt BJ, Germain S. et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19 (01) 58-64.
  • 31 Carmona F, Font J, Azulay M. et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001; 46 (04) 274-279.
  • 32 Llanos C, Izmirly PM, Katholi M. et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60 (10) 3091-3097.
  • 33 Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum Dis Clin North Am 2007; 33 (02) 267-285.
  • 34 Pisoni CN, Brucato A, Ruffatti A. et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62 (04) 1147-1152.
  • 35 Friedman DM, Llanos C, Izmirly J PM. et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, openlabel clinical trial. Arthritis Rheum 2010; 62 (04) 1138-1146.
  • 36 Izmirly PM, Kim MY, Llanos C. et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69 (10) 1827-1830.
  • 37 Ruiz-Irastorza G, Khamashta MA. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2009; 23 (04) 575-582.
  • 38 Østensen M, Khamashta M, Lockshin M. et al. Antiinflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8 (03) 209.
  • 39 Christensen LA, Dahlerup JF, Nielsen MJ. et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28 (10) 1209.